Docket No.: H1890.0201

Application No. 09/313,628 Amendment dated December 27, 2006 Reply to Office Action of December 15, 2006

j...?

AMENDMENTS TO THE CLAIMS

21. (Previously presented) In a method of achieving contraception in a premenopausal human female by administering to the female a contraception effective amount of a contraceptive agent, the improvement which comprises said agent being a combination of a contraception effective amount of a Selective Estrogen Receptor Modulator and an agent which exhibits progestogenic activity, wherein the amount of the agent which exhibits progestogenic activity is effective to ameliorate or eliminate the bleeding side effects of the Selective Estrogen Receptor Modulator.

- 22. (Previously presented) The method of claim 21 wherein the Selective Estrogen Receptor Modulator is clomiphene.
- 23. (Previously presented) The method of claim 21 wherein the Selective Estrogen Receptor Modulator is a benzothiophene.
- 24. (Previously presented) The method of claim 21 wherein the agent which exhibits progestogenic activity is an antiprogestin.
- 25. (Previously presented) The method of claim 24 wherein the antiprogestin is a progesterone receptor antagonist.
- 26. (Previously presented) The method of claim 25 wherein the Selective Estrogen Receptor Modulator is clomiphene.
- 27. (Previously presented) The method of claim 25 wherein the Selective Estrogen Receptor Modulator is a benzothiophene.

Docket No.: H1890.0201

Application No. 09/313,628 Amendment dated December 27, 2006 Reply to Office Action of December 15, 2006

- 28. (Previously presented) The method of claim 24 wherein the amount of antiprogestin is that sufficient to maintain the blood estrogen concentration in the range of about 25 to 125 pg/ml.
- 29. (Previously presented) The method of claim 28 wherein the amount of antiprogestin is that sufficient to maintain the blood estrogen concentration in the range of about 60 to 90 pg/ml.
- 30. (Previously presented) The method of claim 21 wherein the agent which exhibits progestogenic activity expresses both androgenic and progestogenic activity.
- 31. (Previously presented) The method of claim 30 wherein the agent which exhibits progestogenic activity comprises the combination of an androgen and a progestin.
- 32. (Previously presented) The method of claim 30 wherein the agent which exhibits progestogenic activity is a single material which expresses both activities.
- 33. (Previously presented) The method of claim 32 wherein the agent which exhibits progestogenic activity is danazol or levonorgestrel.

34-43 (Canceled)